

Shingles Vaccines Market Set for Rapid Growth: Key Players and Emerging Opportunities 2025 | DataM Intelligence

The Shingles Vaccines Market is estimated to reach at a CAGR of 10.00% during the forecast period 2024-2031.

AUSTIN, TX, UNITED STATES, August 25, 2025 /EINPresswire.com/ -- Overview of the Market:

The [Shingles Vaccines Market](#) has experienced significant growth in recent years, driven by an aging global population and increased awareness of the risks associated with shingles. Shingles, caused by the reactivation of the varicella-zoster virus, primarily affects older adults and can lead to severe complications such as post-herpetic neuralgia. Vaccination has emerged as a crucial preventive measure, leading to a surge in demand for effective vaccines.

“

The Global Shingles Vaccines Market is rapidly growing, driven by aging populations and rising awareness, with key players expanding production to meet increasing demand.”

DataM Intelligence

infrastructure, and strong government initiatives.



To Download Sample Report Here:

<https://www.datamintelligence.com/download-sample/shingles-vaccines-market>

This growth is attributed to factors such as the increasing prevalence of shingles, advancements in vaccine technology, and supportive government policies promoting vaccination. The recombinant vaccine segment, particularly Shingrix, dominates the market due to its high efficacy and safety profile. North America has the highest market share, because of high immunization rates, robust healthcare

Key Highlights from the Report

The global shingles vaccine market is projected to reach at a CAGR of 10.00%.

Recombinant vaccines, particularly Shingrix, dominate the market due to their high efficacy and safety profile.

North America leads the market, supported by high vaccination coverage and a strong healthcare system.

The Asia Pacific region is projected to grow the fastest, fueled by expanding healthcare access and rising awareness.

Government initiatives and national immunization programs play a significant role in market expansion.

Ongoing research and development efforts are focused on improving vaccine formulations and delivery methods.

Market Segmentation:

By Product Type

The Shingles Vaccine Market is divided into three segments: recombinant vaccines, live attenuated vaccines, and subunit vaccinations. Recombinant vaccines, such as Shingrix, have gained prominence due to their enhanced efficacy and safety profile. Live attenuated vaccines, like Zostavax, are also available but have lower efficacy compared to recombinant vaccines. Subunit vaccines are developing as an alternative, offering customized immune responses while remaining safe.

By Age Group

Vaccination is primarily recommended for adults aged 50 and above, with higher priority for those aged 60 and above. This age group is at a higher risk of developing shingles and its complications, making them the key target demographic for vaccine programs.

By End-User

The main end-users of shingles vaccines include hospitals, clinics, and pharmacies. Hospitals and clinics serve as major distribution channels, while pharmacies provide easy access for the general population, enhancing vaccine uptake.

Buy Now & Unlock 360° Market Intelligence: <https://www.datamintelligence.com/buy-now-page?report=shingles-vaccines-market>

Regional Insights:

North America

North America dominates the worldwide shingles vaccine market. The United States, in particular, has a high incidence of shingles, with approximately 1 million cases reported annually. Government initiatives, such as the inclusion of shingles vaccines in national immunization

programs, have contributed to increased vaccination rates and awareness.

Europe

Europe represents a substantial market for shingles vaccines, with countries like Germany, the United Kingdom, and France implementing national immunization programs. Approval and adoption of vaccines like Shingrix have bolstered market growth, supported by strong healthcare infrastructure and public health awareness campaigns.

Asia Pacific

The Asia Pacific region is witnessing rapid growth in the shingles vaccine market, driven by improving healthcare infrastructure and increasing awareness. Countries like Japan and South Korea have initiated vaccination programs targeting older adults, contributing to market expansion. Emerging markets within the region also present opportunities due to rising disposable income and better healthcare access.

Market Dynamics

Market Drivers

Aging Population: The global increase in the elderly population is a significant driver, as older adults are more susceptible to shingles and related complications.

Government Initiatives: National immunization programs and funding for vaccine research have facilitated market growth.

Technological Advancements: Innovations in vaccine development have led to more effective and safer vaccines, encouraging broader adoption.

Market Restraints

Side Effects: Some vaccines may cause mild to moderate side effects, which can lead to hesitancy among potential recipients.

Cost: High vaccine prices can limit access, especially in low-income regions.

Supply Chain Challenges: Distribution and storage issues can affect vaccine availability in certain areas.

Market Opportunities

Emerging Markets: Increasing healthcare access in developing countries presents growth opportunities.

Research and Development: Ongoing R&D can lead to improved vaccine formulations and novel delivery methods.

Public Awareness Campaigns: Educating the public about the benefits of vaccination can drive higher adoption rates.

Frequently Asked Questions (FAQs)

How big is the shingles vaccine market?

Who are the top players in the global shingles vaccine market?

What is the projected growth rate of the shingles vaccine market?

What is the market forecast for shingles vaccines by 2030?

Which region is estimated to dominate the shingles vaccine industry through the forecast period?

Company Insights:

GlaxoSmithKline plc.

Merck & Co., Inc.

SK chemicals

Green Cross Corp

Geneone Life Science

Vaccitech

CanSinoBIO.

Recent Developments:

USA:

On June 5, 2025, a leading pharmaceutical company announced expanded distribution of a next-generation shingles vaccine to rural clinics, aiming to improve access nationwide.

On July 14, 2025, the FDA approved a new age indication for an existing shingles vaccine, allowing use in adults aged 40-49.

Japan:

On June 21, 2025, the Japanese government added the latest recombinant zoster vaccine to its national immunization schedule for seniors over 50.

On August 10, 2025, a domestic biotech firm launched a clinical trial of an innovative shingles vaccine candidate targeting variant strains.

Unlock 360° Market Intelligence with DataM Subscription Services:

<https://www.datamintelligence.com/reports-subscription>

Conclusion:

The Shingles Vaccine Market is poised for substantial growth due to an aging global population,

supportive government initiatives, and technological advancements in vaccine development. Recombinant vaccines such as Shingrix continue to dominate the market, offering high efficacy and safety. While challenges like cost and side effects exist, expanding healthcare infrastructure, ongoing research, and rising public awareness present significant opportunities for continued market expansion.

Related Reports:

[DNA Vaccines Market](#)

[Antibacterial Drugs Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/842889268>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.